We are live on ! Find out more
TCRX icon

TScan Therapeutics
TCRX

54 hedge funds and large institutions have $187M invested in TScan Therapeutics in 2023 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 4

156% more capital invested

Capital invested by funds: $73.2M → $187M (+$114M)

69% more funds holding

Funds holding: 32 → 54 (+22)

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

8.16% more ownership

Funds ownership: 65.66% → 73.82% (+8.2%)

Holders
54
Holders Change
+22
Holders Change %
+68.75%
% of All Funds
0.79%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
22
Increased
13
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$961K
2
Aberdeen Group
Aberdeen Group
United Kingdom
+$916K
3
Marshall Wace
Marshall Wace
United Kingdom
+$506K
4
Millennium Management
Millennium Management
New York
+$454K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$398K

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$458K
2
LBA
Letko, Brosseau & Associates
Quebec, Canada
-$53.6K
3
BlackRock
BlackRock
New York
-$39.9K
4
Northern Trust
Northern Trust
Illinois
-$1.67K
Name Holding Trade Value Shares
Change 		Change in
Stake
ECM
26
ExodusPoint Capital Management
New York
$372K +$292K +63,778 New
State Street
27
State Street
Massachusetts
$356K +$88.8K +19,400 +47%
LCM
28
Laurion Capital Management
New York
$352K +$276K +60,400 New
Man Group
29
Man Group
United Kingdom
$294K +$231K +50,410 New
Balyasny Asset Management
30
Balyasny Asset Management
Illinois
$268K +$211K +45,986 New
6CM
31
683 Capital Management
New York
$252K +$198K +43,198 New
Bank of America
32
Bank of America
North Carolina
$220K +$172K +37,604 +18,802%
DIM
33
DC Investments Management
Virginia
$207K – – –
JP Morgan Chase
34
JP Morgan Chase
New York
$194K +$152K +33,230 New
Goldman Sachs
35
Goldman Sachs
New York
$177K +$139K +30,285 New
CSS
36
Cubist Systematic Strategies
Connecticut
$153K +$120K +26,245 New
Charles Schwab
37
Charles Schwab
California
$129K +$101K +22,104 New
Renaissance Technologies
38
Renaissance Technologies
New York
$127K +$18.3K +4,000 +23%
PFCS
39
Pale Fire Capital SE
Czech Republic
$126K +$22.9K +4,998 +30%
American Century Companies
40
American Century Companies
Missouri
$124K +$9.63K +2,103 +11%
LBA
41
Letko, Brosseau & Associates
Quebec, Canada
$121K -$53.6K -11,700 -36%
VF
42
Virtu Financial
New York
$107K +$84.3K +18,418 New
Walleye Capital
43
Walleye Capital
New York
$104K +$81.4K +17,777 New
Bank of New York Mellon
44
Bank of New York Mellon
New York
$97.2K +$76.3K +16,670 New
PFMU
45
Privium Fund Management (UK)
United Kingdom
$92.3K – – –
YIH
46
Y-Intercept (HK)
Hong Kong
$87.5K +$68.7K +15,005 New
BFM
47
Boothbay Fund Management
New York
$77.5K +$60.9K +13,293 New
AWM
48
Aries Wealth Management
Maine
$58.3K – – –
WPW
49
Waldron Private Wealth
Pennsylvania
$58.3K – – –
Lazard Asset Management
50
Lazard Asset Management
New York
$22K +$18.2K +3,983 New
1
2
3

TCRX Hedge Fund Activity: Q4 2023 in Review

54 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q4 2023, worth a combined $187M — up 156% from $73.2M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new TCRX positions and 0 closed out — a net gain of 22 holders — while 13 added to existing stakes and 4 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $961K. The largest seller was Adage Capital Partners, cutting an estimated $458K.

  • 54 institutional investors held TScan Therapeutics (TCRX) as of Q4 2023, up from 32 in Q3 2023.
  • Funds reported $187M of TScan Therapeutics stock for Q4 2023, up 156% quarter-over-quarter.
  • 22 funds opened new TScan Therapeutics positions in Q4 2023 and 0 closed out, a net change of +22 holders.
  • The largest TScan Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $961K added.
  • The largest TScan Therapeutics seller in Q4 2023 was Adage Capital Partners, an estimated $458K sold.

Based on aggregated 13F filings for Q4 2023.